Sound Pharmaceuticals (SPI) is at the forefront of developing innovative therapeutics aimed at addressing sensorineural hearing loss and tinnitus, conditions that affect millions of individuals in the U.S. The company is pioneering the use of SPI-1005, a proprietary oral formulation of ebselen, which acts as a mimic and inducer of glutathione peroxidase (GPx), a critical antioxidant enzyme in the cochlea. This mechanism allows SPI-1005 to protect the inner ear from noise-induced damage and other forms of ototoxicity, making it a promising candidate for treating conditions such as Meniere’s Disease and hearing loss associated with chemotherapy. The drug has shown efficacy in preclinical and clinical studies, demonstrating its potential to reduce the incidence and severity of noise-induced hearing loss and protect against the ototoxic effects of certain medications.

In addition to otoprotection, SPI is also focused on regenerative therapies for severe to profound hearing loss. The company is developing compounds that inhibit the cyclin-dependent kinase inhibitor 1B (p27Kip1), which can stimulate the regeneration of cells within the cochlea. This approach aims to coax supporting cells to re-enter the cell cycle and proliferate, ultimately leading to the restoration of sensory hair cells and auditory function. The research indicates that these newly dividing cells can differentiate into various cell types necessary for hearing, offering a potential pathway for restoring hearing in individuals with significant hearing loss. Through these advanced technologies, Sound Pharmaceuticals is addressing significant unmet medical needs in the field of otology.

United States

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.

Sound Pharmaceuticals

Company Details